BioPharma Credit PLC Result of AGM (3892O)

TIDMBPCR

RNS Number : 3892O

BioPharma Credit PLC

09 June 2022

BIOPHARMA CREDIT PLC

(THE "COMPANY")

RESULT OF 2022 ANNUAL GENERAL MEETING

The Company is pleased to announce that, at the Annual General Meeting held today, all resolutions put to the meeting were passed on a show of hands.

At the Annual General Meeting it was agreed that Resolutions 12, 13, 15 and 16 should be withdrawn.

The proxy votes received in relation to the resolutions put to the meeting were as follows:

 
                                              %                   %      Votes at          Votes 
                                  Votes                Votes           Chairman's    Withheld(1) 
 Resolutions                        For              Against           Discretion 
 1: To receive 
  and accept the 
  annual report 
  and financial 
  statements                701,371,930   99.99       13,980   0.01             0              0 
                           ------------  ------  -----------  -----  ------------  ------------- 
 2: To approve 
  the Directors' 
  Remuneration Report       701,350,388   99.99       35,522   0.01             0              0 
                           ------------  ------  -----------  -----  ------------  ------------- 
 3: To re-elect 
  Harry Hyman as 
  a Director                701,373,910   99.99       12,000   0.01             0              0 
                           ------------  ------  -----------  -----  ------------  ------------- 
 4: To re-elect 
  Colin Bond as 
  a Director                701,373,910   99.99       12,000   0.01             0              0 
                           ------------  ------  -----------  -----  ------------  ------------- 
 5: To re-elect 
  Duncan Budge as 
  a Director                654,374,400    93.3   47,011,510    6.7             0              0 
                           ------------  ------  -----------  -----  ------------  ------------- 
 6: To re-elect 
  Stephanie Léouzon 
  as a Director             701,383,410   99.99        1,000   0.01             0          1,500 
                           ------------  ------  -----------  -----  ------------  ------------- 
 7: To re-elect 
  Rolf Soderstrom 
  as a Director             701,384,910   99.99        1,000   0.01             0              0 
                           ------------  ------  -----------  -----  ------------  ------------- 
 8: To appoint 
  Ernst & Young 
  LLP as Auditor 
  to the Company            691,330,907   98.57   10,055,003   1.43             0              0 
                           ------------  ------  -----------  -----  ------------  ------------- 
 9: To authorise 
  the Directors 
  to determine the 
  remuneration of 
  the Auditor               701,356,907   99.99       29,003   0.01             0              0 
                           ------------  ------  -----------  -----  ------------  ------------- 
 10: To approve 
  the Company's 
  dividend payment 
  policy                    691,385,910   98.57   10,000,000   1.43             0              0 
                           ------------  ------  -----------  -----  ------------  ------------- 
 11: To authorise 
  the allotment 
  of shares by the 
  Company                   701,017,002   99.99       67,908   0.01             0        301,000 
                           ------------  ------  -----------  -----  ------------  ------------- 
 12: To authorise           Resolution Withdrawn 
  the allotment 
  of shares by the 
  Company 
                           --------------------------------------------------------------------- 
 13: To authorise           Resolution Withdrawn 
  the allotment 
  of shares by the 
  Company 
                           --------------------------------------------------------------------- 
 14: To authorise 
  the disapplication 
  of pre-emption 
  rights                    691,301,812   98.56   10,084,098   1.44             0              0 
                           ------------  ------  -----------  -----  ------------  ------------- 
 15: To authorise           Resolution Withdrawn 
  the disapplication 
  of pre-emption 
  rights 
                           --------------------------------------------------------------------- 
 16: To authorise           Resolution Withdrawn 
  the disapplication 
  of pre-emption 
  rights 
                           --------------------------------------------------------------------- 
 17: To authorise 
  the Company to 
  make market purchases 
  of ordinary shares        701,357,930   99.99       27,980   0.01             0              0 
                           ------------  ------  -----------  -----  ------------  ------------- 
 18: To authorise 
  the Company to 
  hold general meetings 
  on 14 clear days' 
  notice                    701,355,430   99.99       30,480   0.01             0              0 
                           ------------  ------  -----------  -----  ------------  ------------- 
 

1. A 'vote withheld' is not a vote under English law and is not counted in the calculation of votes 'for' or 'against' a resolution.

A copy of resolutions 14, 17 and 18 has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

9 June 2022

Enquiries

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

[phone]

Buchanan

[phone] / [e-mail]

David Rydell

Mark Court

Jamie Hooper

Henry Wilson

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGSSAFMUEESEDM

(END) Dow Jones Newswires

June 09, 2022 12:39 ET (16:39 GMT)